Chugai Pharmaceutical Co., Ltd. (CHGCF)
- Previous Close
32.43 - Open
32.43 - Bid --
- Ask --
- Day's Range
32.43 - 32.43 - 52 Week Range
26.00 - 43.72 - Volume
412 - Avg. Volume
490 - Market Cap (intraday)
54.765B - Beta (5Y Monthly) 0.48
- PE Ratio (TTM)
25.34 - EPS (TTM)
1.28 - Earnings Date --
- Forward Dividend & Yield 0.56 (1.72%)
- Ex-Dividend Date Jun 27, 2024
- 1y Target Est
--
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng. It has various development product candidates in the areas of oncology, immunology, neuroscience, hematology, ophthalmology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances and collaboration with Roche Group. The company was founded in 1925 and is headquartered in Chuo, Japan. Chugai Pharmaceutical Co., Ltd. operates as a subsidiary of Roche Holding Ltd.
www.chugai-pharm.co.jp7,604
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: CHGCF
Performance Overview: CHGCF
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CHGCF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CHGCF
Valuation Measures
Market Cap
51.67B
Enterprise Value
46.73B
Trailing P/E
25.30
Forward P/E
24.21
PEG Ratio (5yr expected)
8.30
Price/Sales (ttm)
7.97
Price/Book (mrq)
5.03
Enterprise Value/Revenue
0.05
Enterprise Value/EBITDA
0.11
Financial Highlights
Profitability and Income Statement
Profit Margin
31.50%
Return on Assets (ttm)
15.01%
Return on Equity (ttm)
21.20%
Revenue (ttm)
1.04T
Net Income Avi to Common (ttm)
326.37B
Diluted EPS (ttm)
1.28
Balance Sheet and Cash Flow
Total Cash (mrq)
764.57B
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
287.75B
Research Analysis: CHGCF
Company Insights: CHGCF
CHGCF does not have Company Insights